Aarti Speciality Chemicals, a wholly-owned subsidiary of Aarti Drugs (Aarti Drugs), stands out to be one of the beneficiaries of the Government of India s recently approved Production Linked Incentive (PLI) for the Pharmaceutical Sector.
Government of India s Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers recently launched a Production Linked Incentive (PLI) Scheme to promote domestic manufacturing by incentivising pharmaceutical manufacturers to set-up greenfield projects in India with a minimum domestic value addition in four different target segments (Two in Fermentation based - at least 90% and Two in the Chemical Synthesis based - at least 70%) with a total outlay of Rs. 6,940 crores. The objective of the scheme is achieving self-reliance and reducing import dependence in these critical Key Starting Materials (KSMs)/ Drug Intermediates/ Active Pharmaceutical Ingredients (APIs) in the country.
Aarti Drugs share rises 8% after arm gets nod under pharma PLI scheme
Aarti Drugs share touched an intraday high of Rs 717.85 rising 7.83% against previous close of Rs 665.70 on BSE
BusinessToday.In | March 8, 2021 | Updated 14:56 IST
Aarti Drugs stock trades higher than 5 day, 20 day, 50 day and 200 day moving averages but lower than 100 day moving averages.
Aarti Drugs share rose nearly 8% today after the company s subsidiary received approval under Production Linked Incentive (PLI) scheme for the pharmaceutical sector. The pharma stock opened with a gain of 6.11% at Rs 706.35 today. The mid cap stock touched an intraday high of Rs 717.85 rising 7.83% against previous close of Rs 665.70 on BSE.
Aarti Drugs: The shares ended the trading session higher by 3.94 per cent on the BSE.
Aarti Drugs shares soared nearly 4 per cent in a subdued market after the company s subsidiary received approval under Production Linked Incentive (PLI) scheme for the pharmaceutical sector. The shares of Aarti Drugs ended the trading session at Rs 691.90, higher by 3.94 per cent, on the BSE. Aarti Speciality Chemicals (ASCL), a wholly-owned subsidiary of Aarti Drugs, stands out to be one of the beneficiaries of the Government of India s recently approved Production Linked Incentive (PLI) for the pharmaceutical sector, the company said in a regulatory filing to the stock exchanges.
Read more about Sensex closes almost flat, Nifty fails to reclaim 15,000 on Business Standard. Domestic equity benchmarks ended with small gains on Monday. Banks, IT, metals and pharma stocks advanced while autos, financials and FMCG shares declined. The Nifty closed near the 15,000 mark.
Apple is preparing to move up to 10% of production for the iPhone 12 from China to India, reports claim, with assembly partner Foxconn said to be working on units for sale within the country and for the export market.